Hubei Goto Biopharm Co.,Ltd.

Equities

300966

CNE100004K94

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-13 pm EDT 5-day change 1st Jan Change
19.47 CNY -4.18% Intraday chart for Hubei Goto Biopharm Co.,Ltd. +7.21% -15.24%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hubei Goto Biopharm Co.,Ltd. Proposes Final Cash Dividend for 2023 CI
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Certain A Shares of Hubei Goto Biopharm Co.,Ltd. are subject to a Lock-Up Agreement Ending on 9-APR-2024. CI
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Hubei Goto Biopharm Issues $53 Million Convertible Bonds MT
Hubei Goto Biopharm to Guarantee 46% of Unit’s Loan MT
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Hubei Goto Biopharm Co.,Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 31 May 2022 CI
Hubei Goto Biopharm Co.,Ltd. Approves Cash Dividend for 2021 CI
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Hubei Goto Biopharm Co.,Ltd. Proposes Cash Dividend for 2021 CI
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Certain A Shares of Hubei Goto Biopharm Co.,Ltd. are subject to a Lock-Up Agreement Ending on 9-APR-2022. CI
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Hubei Goto Biopharm Co.,Ltd. Announces Executive Changes CI
Hubei Goto Biopharm : to List 1.5 Million Shares Post IPO Lockup; Shares Jump 4% MT
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Hubei Goto Biopharm Co.,Ltd. has completed an IPO in the amount of CNY 238.96 million. CI
Hubei Goto Biopharm Co.,Ltd. has filed an IPO. CI
Yicheng Goto Pharmaceuticals Co., Ltd announced that it has received funding from Shenzhen Capital Group Co., Ltd.. CI
Chart Hubei Goto Biopharm Co.,Ltd.
More charts
Hubei Goto Biopharm Co Ltd is a China-based company mainly engaged in the research and development, production and sales of steroidal drug raw materials. The Company's main products are starting materials and intermediates required for the production of steroid drugs. The starting materials refer to the products obtained from the conversion of plant sterols through biological fermentation technology. These products are important raw materials for downstream pharmaceutical intermediates and active pharmaceutical ingredient manufacturers and belong to the upstream products in the steroid drug industry chain. The Company's intermediate products mainly include sex hormone intermediates, progesterone intermediates, corticosteroid intermediates and other products.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 300966 Stock
  4. News Hubei Goto Biopharm Co.,Ltd.
  5. Hubei Goto Biopharm Issues $53 Million Convertible Bonds
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW